Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
CSBR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.60 - $11.99
Previous CloseN/A
Volume27.06K
Average Volume (3M)29.81K
Market Cap
$104.67M
Enterprise Value$64.29M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$6.44M
Price to Earnings (P/E)16.0
Beta0.42
Next Earnings
Jul 17, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding13,826,904
10 Day Avg. Volume52,751
30 Day Avg. Volume29,806
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)14.20
Price to Sales (P/S)0.00
P/FCF Ratio60.77
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue0.30
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda17.57
Forecast
1Y Price Target
$12.00Price Target Upside54.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Champions Oncology News
PremiumCompany Announcements
Champions Oncology Reports Record Revenue and Strategic Growth
PremiumCompany Announcements
Champions Oncology Achieves Record Revenue and Profit
Options Prices
Currently, No data available
---
Ownership Overview
14.20% Insiders
3.07% Mutual Funds
33.73% Other Institutional Investors
46.58% Public Companies and Individual Investors
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $3.60 and its highest was $11.99 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $104.67M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Jul 17, 2025 which is in 18 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Mar 11, 2025. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.37.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Undervalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate is -0.2.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,826,904 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.36 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
Champions Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (54.64% Upside)
$12.00 (54.64% Upside)
Blogger Sentiment
Bullish
CSBR Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.56%
12-Months-Change
Fundamentals
Return on Equity
376.84%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology (CSBR) is a biotechnology company focused on advancing personalized medicine in oncology. The company operates primarily in the life sciences sector, offering innovative drug discovery and development solutions. Its core services include the development and utilization of advanced technologies and platforms to assist pharmaceutical companies and academic institutions in accelerating the development of anti-cancer drugs and therapies.
CSBR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant positive developments such as record-breaking revenue, successful data licensing, and improved financial metrics. However, challenges in the biotech sector and uncertainties regarding future data revenue contributions were highlighted. Despite the challenges, the company is optimistic about long-term growth.Read More>Technical Analysis
Tonix Pharma
―
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Seer
―
Elicio Therapeutics
―